Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Director Gordon R. Bernard sold 2,050 shares of the firm’s stock in a transaction on Monday, June 17th. The shares were sold at an average price of $6.19, for a total transaction of $12,689.50. Following the completion of the transaction, the director now directly owns 95,388 shares in the company, valued at approximately $590,451.72. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Shares of CPIX stock opened at $6.30 on Monday. Cumberland Pharmaceuticals, Inc. has a 52 week low of $4.83 and a 52 week high of $7.00. The company has a current ratio of 2.07, a quick ratio of 1.67 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $97.88 million, a PE ratio of -52.50 and a beta of 0.14.
Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported $0.09 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.22. Cumberland Pharmaceuticals had a negative net margin of 10.57% and a positive return on equity of 2.54%. The business had revenue of $11.90 million for the quarter, compared to the consensus estimate of $10.70 million. On average, equities analysts expect that Cumberland Pharmaceuticals, Inc. will post 0.28 earnings per share for the current year.
A hedge fund recently raised its stake in Cumberland Pharmaceuticals stock. Stonepine Capital Management LLC increased its position in shares of Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) by 7.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,313,429 shares of the specialty pharmaceutical company’s stock after buying an additional 95,028 shares during the period. Cumberland Pharmaceuticals comprises approximately 7.0% of Stonepine Capital Management LLC’s holdings, making the stock its 4th biggest holding. Stonepine Capital Management LLC owned about 8.46% of Cumberland Pharmaceuticals worth $7,920,000 at the end of the most recent quarter. Institutional investors own 31.72% of the company’s stock.
A number of equities analysts have recently commented on the stock. Zacks Investment Research raised shares of Cumberland Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $7.00 target price on the stock in a research note on Friday, May 17th. TheStreet raised shares of Cumberland Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Wednesday, April 10th.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.
Read More: Buyback For Investors Defined
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.